Kwaliteitsstandaard atypische parkinsonismen

Pagina 242 121. Rolinski M, F.C., Maidment I, et al. , Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. 2012. 122. Zesiewicz, T.A., et al., Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2010. 74 (11): p. 924-31. 123. Seppi, K., et al., The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord, 2011. 26 Suppl 3 : p. S42-80. 124. Ford, B., Pain in Parkinson's disease. Mov Disord, 2010. 25 Suppl 1 : p. S98-103. 125. Tassorelli, C., et al., Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord, 2014. 20 (11): p. 1140-4. 126. Bruno, V., et al., Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease. Can J Neurol Sci, 2018. 45 (1): p. 23-29. 127. Wiblin, L., et al., The Importance of Connection to Others in QoL in MSA and PSP. Parkinsons Dis, 2017. 2017 : p. 5283259. 128. Wiblin, L., M. Lee, and D. Burn, Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy. Parkinsonism Relat Disord, 2017. 34 : p. 7-14. 129. A, R.v., Handreiking voor multidisciplinaire parkinsonzorg in het verpleeghuis . 2011, Verenso, ParkinsonNet, Parkinson Vereniging: Utrecht. 130. Keus, S., Munneke, M., Graziano, M., Paltamaa, J. et al. . European Physiotherapy Guideline for Parkinson's Disease. Developed with twenty Euopean professional associations. . 2014 131. Nieuwboer, A., et al., Motor learning in Parkinson's disease: limitations and potential for rehabilitation. Parkinsonism Relat Disord, 2009. 15 Suppl 3 : p. S53-8. 132. Paul, S.S., L.E. Dibble, and D.S. Peterson, Motor learning in people with Parkinson's disease: Implications for fall prevention across the disease spectrum. Gait Posture, 2018. 61 : p. 311-319. 133. KNGF, KNGF richtlijn ziekte van Parkinson Informatie over fysiotherapie voor verwijzers. . 2017. 134. Subramanian, I., Complementary and Alternative Medicine and Exercise in Nonmotor Symptoms of Parkinson's Disease. Int Rev Neurobiol, 2017. 134 : p. 1163-1188. 135. KNGF. KNGF-richtlijn ziekte van Parkinson. . 2017; Available from: https://www.parkinsonnet.nl/media/15336575/praktijkrichtlijn__kngf_richtlijn_ziekte_van_parkinson_ 2017.pdf . 136. Morris, M.S., Lansek, R.N. , Parkinson’s disease: a team approach. . 1997. 137. Colosimo, C., Riley,. D.E. and Wenning, G.K., Handbook of Atypical Parkinsonism. . Vol. Chapter 8: Non- pharmacological treatment for atypical parkinsonism. . 2011. 138. Sturkenboom, I., Thijssen, M., Gons-van Elsacker, J., Jansen, I. et al Richtlijn Ergotherapie bij de ziekte van Parkinson. 2008; Available from: https://www.parkinsonnet.nl/media/5351/ergotherapie-bij- parkinson.pdf . 139. Sturkenboom, I., OTiP studie. Occupational therapy for people with Parkinson’s disease: towards evidence-informed care. . 2016, The Netherlands: Radboud University Nijmegen. 140. Friginal-Ruiz AB, L.A., Percutaneous Endoscopic Gastrostomy: A Practical Overview on Its Indications, Placement Conditions, Management, and Nursing Care. Gastroenterol Nurs. , 2015 Sep-Oct; (38(5)): p. 354-66. 141. Wenning, G.K., et al., Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord, 1997. 12 (2): p. 133-47. 142. Silber, M.H. and S. Levine, Stridor and death in multiple system atrophy. Mov Disord, 2000. 15 (4): p. 699- 704. 143. Stefanova, N., et al., Multiple system atrophy: an update. Lancet Neurol, 2009. 8 (12): p. 1172-8. 144. Louter, M., Pelleboer, R.H., van den Broek, G.B., Post, B. et al. , Nachtelijke stridor bij multipele systeematrofie casuïstiek. NTVG 2011(155:A3621).